Tadalafil Tablet, Coated
Product Images NDC 46708-177

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 46708-177). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Tadalafil Structure)

Chemical structure diagram of tadalafil, the active ingredient shown in the image. The diagram depicts the molecular arrangement of tadalafil with its characteristic fused rings and functional groups.*

FDA Label Image

Figure 1 (Tadalafil Figure1)

Four line charts depicting the difference in blood pressure (BP) measurements between tadalafil and placebo over 96 hours. Charts show standing systolic BP, standing diastolic BP, supine systolic BP, and supine diastolic BP, with BP differences on the y-axis and time in hours on the x-axis.*

FDA Label Image

Figure 2 (Tadalafil Figure2)

Two line graphs depicting the effects on systolic blood pressure over 24 hours post-dose. The top graph shows standing systolic blood pressure measured in mmHg, comparing tadalafil 20 mg with doxazosin 8 mg and placebo with doxazosin 8 mg. The bottom graph presents supine systolic blood pressure under the same conditions. The x-axis represents time in hours post-dose, and the y-axis shows changes in systolic blood pressure in mmHg.*

FDA Label Image

Figure 3 (Tadalafil Figure3)

A line graph depicting systolic blood pressure (mmHg) over 12 hours after administration of tadalafil or placebo combined with doxazosin. The x-axis represents time in hours, and the y-axis shows systolic BP changes. Four lines compare 20 mg tadalafil and placebo groups at two different dosing times (08:00 and 20:00) alongside a constant 8 mg doxazosin dose.*

FDA Label Image

Figure 4 (Tadalafil Figure4)

A line graph showing plasma tadalafil concentration (µg/L) over time (hours) for three dosing regimens: single 20 mg dose, single 5 mg dose, and once-daily 5 mg dose after 5 consecutive days. The graph displays concentration peaks and declines with error bars for variability.*

FDA Label Image

Figure 5 (Tadalafil 5figure)

A line graph showing mean IPSS changes in BPH patients over 12 weeks of treatment. It compares Tadalafil 5 mg tablets to placebo, charting change from baseline in IPSS total score versus duration of treatment in weeks. The graph indicates a greater decrease in scores with Tadalafil 5 mg compared to placebo throughout the study period.*

FDA Label Image

Figure 6 (Tadalafil 6figure)

A line graph depicting mean changes in IPSS total score from baseline in BPH patients over 12 weeks of treatment with Tadalafil 5 mg tablets compared to placebo. The x-axis represents treatment duration in weeks, and the y-axis shows change from baseline IPSS score. The graph includes statistical significance markers (p<0.01).*

FDA Label Image

Figure 7 (Tadalafil 7figure)

A line graph titled 'Mean Total IPSS Changes By Visit in BPH Patients Taking Tadalafil Tablet for Once Daily Use Together With Finasteride' showing LS mean change from baseline over 26 weeks. It compares two groups: Tadalafil/Finasteride and Placebo/Finasteride, with measurements at weeks 0, 4, 12, and 26. The graph highlights differences in symptom scores between groups over time, with statistical significance markers at certain points.*

FDA Label Image

Figure 8 (Tadalafil 8figure)

A line graph depicting mean changes in IPSS total score over 12 weeks of treatment for ED/BPH patients. The graph compares tadalafil tablet 5 mg versus placebo, showing a more substantial decrease in IPSS score with tadalafil. The x-axis represents treatment duration in weeks, and the y-axis represents change from baseline in IPSS total score.*

FDA Label Image

30 Tablets In 1 Carton (Tadalafil 25mg)

Packaging label for Tadalafil Tablets, USP 2.5 mg oral coated tablets by Alembic Pharmaceuticals Limited. The label displays the product name, strength (2.5 mg), dosage form (tablets), quantity (30 tablets in 2 blisters of 15), and specifies the tablets should not be split. It includes directions for once daily use and the NDC number 46708-177-15.*

FDA Label Image

30 Tablets In 1 Bottle (Tadalafil 5mg)

Label for Tadalafil Tablets USP 5 mg by Alembic Pharmaceuticals Limited. The label shows the active ingredient strength of 5 mg per film-coated tablet, the package contains 30 tablets, and storage instructions are included. The label also features the NDC number 46708-178-30, barcode, manufacturer details, and dosing caution information.*

FDA Label Image

30 Tablets In 1 Bottle (Tadalafil 10mg)

Label for Tadalafil Tablets, USP 10 mg oral film-coated tablets by Alembic Pharmaceuticals Limited. The label includes storage instructions, a warning to keep out of reach of children, a barcode, NDC 46708-179-30, and a quantity of 30 tablets. It states tablets should not be split and to take the entire dose.*

FDA Label Image

30's Bottle Pack (Tadalafil 20mg)

Label for Tadalafil Tablets, USP 20 mg coated tablets by Alembic Pharmaceuticals Limited. The label includes storage instructions, usage warnings, quantity of 30 tablets per container, and the NDC 46708-180-30. It advises that tablets should not be split and the entire dose should be taken.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.